STOCK TITAN

[Form 4] SANGAMO THERAPEUTICS, INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Sangamo Therapeutics (SGMO) insider filing: The SVP–Chief Development Officer reported a routine tax-withholding transaction tied to RSU vesting. On 10/22/2025, 43,741 shares were surrendered at $0.66 under Code F to cover mandatory taxes from an RSU vesting event. Following the transaction, beneficial ownership stands at 722,348 shares (direct).

The filing notes RSU activity and schedules: 45,321 shares vested on 10/22/2025 from a 1/22/2024 grant; 89,063 shares from that grant are scheduled to vest in equal quarterly installments through 1/22/2026. It also lists 10,020 shares from a 2/24/2023 grant vesting quarterly through 2/24/2026 and 120,000 shares from a 2/25/2025 grant vesting one-fourth on 2/25/2026 with the remainder in eight equal quarterly installments thereafter, each subject to continuous service.

Sangamo Therapeutics (SGMO) insider filing: Il SVP–Chief Development Officer ha riportato una normale transazione di trattenuta fiscale legata alla vesting di RSU. Il 22/10/2025, sono state cedute 43.741 azioni al prezzo di 0,66 dollari ai fini del pagamento delle tasse obbligatorie derivanti da un evento di vesting di RSU. Dopo la transazione, la proprietà beneficiaria ammonta a 722.348 azioni (dirette).

La dichiarazione riporta attività e calendari RSU: 45.321 azioni vestite il 22/10/2025 provenienti da una concessione del 22/01/2024; 89.063 azioni di quella concessione sono previste di vestire in rate trimestrali uguali fino al 22/01/2026. Riporta inoltre 10.020 azioni provenienti da una concessione del 24/02/2023 che vestono trimestralmente fino al 24/02/2026 e 120.000 azioni da una concessione del 25/02/2025 vesting in una quarta parte il 25/02/2026 con il resto in otto rate trimestrali uguali successive, ciascuna soggetta al continuo servizio.

Dossier de Sangamo Therapeutics (SGMO) por insiders: El SVP–Chief Development Officer reportó una transacción de retención fiscal de rutina vinculada al vesting de RSU. El 22/10/2025, se entregaron 43.741 acciones a 0,66 $ bajo el Código F para cubrir los impuestos obligatorios de un evento de vesting de RSU. Tras la transacción, la titularidad beneficiaria es de 722.348 acciones (directas).

El filing señala actividad y calendarios RSU: 45.321 acciones vestidas el 22/10/2025 provenientes de una concesión del 22/01/2024; 89.063 acciones de esa concesión están programadas para vestirse en cuotas trimestrales iguales hasta el 22/01/2026. También lista 10.020 acciones de una concesión del 24/02/2023 vesting trimestral hasta el 24/02/2026 y 120.000 acciones de una concesión del 25/02/2025 vesting en una cuarta parte el 25/02/2026 y el resto en ocho cuotas trimestrales iguales, cada una sujeta al servicio continuo.

Sangamo Therapeutics (SGMO) 내부자 공시: SVP–개발담당 최고책임자는 RSU 가속 부여에 따른 일반적인 세금 원천징수 거래를 보고했다. 2025년 10월 22일, RSU 가속 이벤트에서의 의무세를 충당하기 위해 F 코드 하에 0.66달러에 43,741주가 양도되었다. 거래 후 유익한 소유권은 722,348주(직접 보유)로 유지된다.

공시는 RSU 활동 및 일정에 대해: 2025년 10월 22일에 45,321주가 2024년 1월 22일 부여로부터 vesting되었고; 그 부여의 89,063주는 2026년 1월 22일까지 같은 분기로 vesting될 예정이다. 또한 2023년 2월 24일 부여의 10,020주는 2026년 2월 24일까지 분기별로 vesting되며, 2025년 2월 25일 부여의 120,000주는 2026년 2월 25일에 4분의 1이 vesting되고 나머지는 이후 8개 분기별로 동일하게 vesting되며, 각각은 지속적인 서비스에 의존한다.

Dossier Sangamo Therapeutics (SGMO) des initiés : Le SVP–CVO a signalé une transaction routinière de retenue d’impôt liée au vesting des RSU. Le 22/10/2025, 43 741 actions ont été cédées à 0,66 $ sous le code F pour couvrir les impôts obligatoires d’un événement de vesting RSU. Après la transaction, la propriété bénéficiaire s’élève à 722 348 actions (directes).

Le dossier indique l’activité RSU et les calendriers : 45 321 actions vestées le 22/10/2025 provenant d’une attribution du 22/01/2024 ; 89 063 actions de cette attribution sont prévues de vesting en versements trimestriels égaux jusqu’au 22/01/2026. Il répertorie également 10 020 actions d’une attribution du 24/02/2023 vesting trimestriellement jusqu’au 24/02/2026 et 120 000 actions d’une attribution du 25/02/2025 vesting en un quart le 25/02/2026 avec le reste réparti sur huit versements trimestriels égaux par la suite, chacun soumis au service continu.

Sangamo Therapeutics (SGMO) Insider-Filing: Der Senior Vice President – Chief Development Officer meldete eine routinemäßige steuerliche Quellenabzugstransaktion im Zusammenhang mit RSU-Vesting. Am 22.10.2025 wurden 43.741 Aktien zu 0,66 $ unter Code F übergeben, um die obligatorischen Steuern aus einem RSU-Vesting-Ereignis zu decken. Nach der Transaktion beläuft sich das erworbene Eigentum auf 722.348 Aktien (direkt).

Das Filing vermerkt RSU-Aktivität und -Zeitpläne: 45.321 Aktien vesteten am 22.10.2025 aus einer Gewährung vom 22.01.2024; 89.063 Aktien dieser Gewährung sollen in gleichen vierteljährlichen Raten bis zum 22.01.2026 vesten. Es listet außerdem 10.020 Aktien aus einer Gewährung vom 24.02.2023 auf, die vierteljährlich bis zum 24.02.2026 vesten, und 120.000 Aktien aus einer Gewährung vom 25.02.2025, die am 25.02.2026 vierteljährlich vesten, mit dem Rest in acht gleichen quartalsweisen Raten danach, jeweils unter Fortsetzung des Dienstverhältnisses.

تقرير داخلي لشركة Sangamo Therapeutics (SGMO): أبلغ نائب الرئيس الأول-المدير التنموي عن صفقة حجز ضرائب روتينية مرتبطة بحدوث vesting لـ RSU. في 22/10/2025، تم التخلي عن 43,741 سهماً بسعر 0.66 دولار وفق رمز F لتغطية الضرائب الإلزامية الناتجة عن حدث vesting لـ RSU. بعد الصفقة، الملكية المستفيدة تقف عند 722,348 سهماً (مباشرة).

يذكر التقرير نشاط RSU والجداول: 45,321 سهماً vestت في 22/10/2025 من منحة بتاريخ 22/01/2024؛ 89,063 سهماً من تلك المنحة من المتوقع vestingها على أقساط ربعية متساوية حتى 22/01/2026. كما يرد 10,020 سهماً من منحة بتاريخ 24/02/2023 vesting ربعي حتى 24/02/2026 و120,000 سهماً من منحة بتاريخ 25/02/2025 vesting بنسبة ربع واحد في 25/02/2026 مع الباقي في ثمانية أقساط ربعية متساوية بعدها، كل منها رهينة بالخدمة المستمرة.

Positive
  • None.
Negative
  • None.

Sangamo Therapeutics (SGMO) insider filing: Il SVP–Chief Development Officer ha riportato una normale transazione di trattenuta fiscale legata alla vesting di RSU. Il 22/10/2025, sono state cedute 43.741 azioni al prezzo di 0,66 dollari ai fini del pagamento delle tasse obbligatorie derivanti da un evento di vesting di RSU. Dopo la transazione, la proprietà beneficiaria ammonta a 722.348 azioni (dirette).

La dichiarazione riporta attività e calendari RSU: 45.321 azioni vestite il 22/10/2025 provenienti da una concessione del 22/01/2024; 89.063 azioni di quella concessione sono previste di vestire in rate trimestrali uguali fino al 22/01/2026. Riporta inoltre 10.020 azioni provenienti da una concessione del 24/02/2023 che vestono trimestralmente fino al 24/02/2026 e 120.000 azioni da una concessione del 25/02/2025 vesting in una quarta parte il 25/02/2026 con il resto in otto rate trimestrali uguali successive, ciascuna soggetta al continuo servizio.

Dossier de Sangamo Therapeutics (SGMO) por insiders: El SVP–Chief Development Officer reportó una transacción de retención fiscal de rutina vinculada al vesting de RSU. El 22/10/2025, se entregaron 43.741 acciones a 0,66 $ bajo el Código F para cubrir los impuestos obligatorios de un evento de vesting de RSU. Tras la transacción, la titularidad beneficiaria es de 722.348 acciones (directas).

El filing señala actividad y calendarios RSU: 45.321 acciones vestidas el 22/10/2025 provenientes de una concesión del 22/01/2024; 89.063 acciones de esa concesión están programadas para vestirse en cuotas trimestrales iguales hasta el 22/01/2026. También lista 10.020 acciones de una concesión del 24/02/2023 vesting trimestral hasta el 24/02/2026 y 120.000 acciones de una concesión del 25/02/2025 vesting en una cuarta parte el 25/02/2026 y el resto en ocho cuotas trimestrales iguales, cada una sujeta al servicio continuo.

Sangamo Therapeutics (SGMO) 내부자 공시: SVP–개발담당 최고책임자는 RSU 가속 부여에 따른 일반적인 세금 원천징수 거래를 보고했다. 2025년 10월 22일, RSU 가속 이벤트에서의 의무세를 충당하기 위해 F 코드 하에 0.66달러에 43,741주가 양도되었다. 거래 후 유익한 소유권은 722,348주(직접 보유)로 유지된다.

공시는 RSU 활동 및 일정에 대해: 2025년 10월 22일에 45,321주가 2024년 1월 22일 부여로부터 vesting되었고; 그 부여의 89,063주는 2026년 1월 22일까지 같은 분기로 vesting될 예정이다. 또한 2023년 2월 24일 부여의 10,020주는 2026년 2월 24일까지 분기별로 vesting되며, 2025년 2월 25일 부여의 120,000주는 2026년 2월 25일에 4분의 1이 vesting되고 나머지는 이후 8개 분기별로 동일하게 vesting되며, 각각은 지속적인 서비스에 의존한다.

Dossier Sangamo Therapeutics (SGMO) des initiés : Le SVP–CVO a signalé une transaction routinière de retenue d’impôt liée au vesting des RSU. Le 22/10/2025, 43 741 actions ont été cédées à 0,66 $ sous le code F pour couvrir les impôts obligatoires d’un événement de vesting RSU. Après la transaction, la propriété bénéficiaire s’élève à 722 348 actions (directes).

Le dossier indique l’activité RSU et les calendriers : 45 321 actions vestées le 22/10/2025 provenant d’une attribution du 22/01/2024 ; 89 063 actions de cette attribution sont prévues de vesting en versements trimestriels égaux jusqu’au 22/01/2026. Il répertorie également 10 020 actions d’une attribution du 24/02/2023 vesting trimestriellement jusqu’au 24/02/2026 et 120 000 actions d’une attribution du 25/02/2025 vesting en un quart le 25/02/2026 avec le reste réparti sur huit versements trimestriels égaux par la suite, chacun soumis au service continu.

Sangamo Therapeutics (SGMO) Insider-Filing: Der Senior Vice President – Chief Development Officer meldete eine routinemäßige steuerliche Quellenabzugstransaktion im Zusammenhang mit RSU-Vesting. Am 22.10.2025 wurden 43.741 Aktien zu 0,66 $ unter Code F übergeben, um die obligatorischen Steuern aus einem RSU-Vesting-Ereignis zu decken. Nach der Transaktion beläuft sich das erworbene Eigentum auf 722.348 Aktien (direkt).

Das Filing vermerkt RSU-Aktivität und -Zeitpläne: 45.321 Aktien vesteten am 22.10.2025 aus einer Gewährung vom 22.01.2024; 89.063 Aktien dieser Gewährung sollen in gleichen vierteljährlichen Raten bis zum 22.01.2026 vesten. Es listet außerdem 10.020 Aktien aus einer Gewährung vom 24.02.2023 auf, die vierteljährlich bis zum 24.02.2026 vesten, und 120.000 Aktien aus einer Gewährung vom 25.02.2025, die am 25.02.2026 vierteljährlich vesten, mit dem Rest in acht gleichen quartalsweisen Raten danach, jeweils unter Fortsetzung des Dienstverhältnisses.

تقرير داخلي لشركة Sangamo Therapeutics (SGMO): أبلغ نائب الرئيس الأول-المدير التنموي عن صفقة حجز ضرائب روتينية مرتبطة بحدوث vesting لـ RSU. في 22/10/2025، تم التخلي عن 43,741 سهماً بسعر 0.66 دولار وفق رمز F لتغطية الضرائب الإلزامية الناتجة عن حدث vesting لـ RSU. بعد الصفقة، الملكية المستفيدة تقف عند 722,348 سهماً (مباشرة).

يذكر التقرير نشاط RSU والجداول: 45,321 سهماً vestت في 22/10/2025 من منحة بتاريخ 22/01/2024؛ 89,063 سهماً من تلك المنحة من المتوقع vestingها على أقساط ربعية متساوية حتى 22/01/2026. كما يرد 10,020 سهماً من منحة بتاريخ 24/02/2023 vesting ربعي حتى 24/02/2026 و120,000 سهماً من منحة بتاريخ 25/02/2025 vesting بنسبة ربع واحد في 25/02/2026 مع الباقي في ثمانية أقساط ربعية متساوية بعدها، كل منها رهينة بالخدمة المستمرة.

Sangamo Therapeutics (SGMO) 内幕交易申报: 高级副总裁—开发主管报告了一笔与 RSU 授予日归属相关的日常税务代扣交易。2025年10月22日,为了覆盖 RSU 授予事件产生的强制税款,按 F 码以每股0.66美元的价格交割了43,741股。交易完成后,实际控制权为722,348股(直接持有)。

申报中提及 RSU 活动及计划:2025年10月22日有45,321股自2024年1月22日授予以来归属;该授予的89,063股计划在2026年1月22日前按每季度等额分期归属。并列出2023年2月24日授予的10,020股将按季度至2026年2月24日归属,2025年2月25日授予的120,000股将于2026年2月25日一次归属四分之一,余下部分随后以八个等额季度分期归属,每期均需持续服务。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dubois-Stringfellow Nathalie

(Last) (First) (Middle)
C/O SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.

(Street)
RICHMOND CA 94084

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP-CHIEF DEVELOPMENT OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 F 43,741(1) D $0.66 722,348(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
2. Includes: (a) 45,321 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 10,020 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
/s/ Scott Willoughby, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SGMO’s insider report on Form 4?

A tax-withholding disposition under Code F: 43,741 shares surrendered on 10/22/2025 to cover taxes on RSU vesting.

At what price were the SGMO shares withheld for taxes?

The issuer’s closing stock price of $0.66 per share on 10/22/2025.

How many SGMO shares does the insider own after the transaction?

Beneficial ownership is 722,348 shares (direct).

Did the insider sell shares on the open market?

No. The filing states the shares were surrendered solely for mandatory tax withholding and not a discretionary trade.

What RSU tranches are referenced for SGMO?

45,321 shares vested on 10/22/2025; 89,063 remain scheduled through 1/22/2026; 10,020 vest through 2/24/2026; 120,000 vest starting 2/25/2026 with eight quarterly installments thereafter.

Whose position is reported in this SGMO filing?

An officer serving as SVP–Chief Development Officer.
Sangamo Therapeutics Inc

NASDAQ:SGMO

SGMO Rankings

SGMO Latest News

SGMO Latest SEC Filings

SGMO Stock Data

191.07M
295.24M
2.16%
16.96%
4.96%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RICHMOND